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Abstract
The coxsackie- and adenovirus receptor (CXADR) is a member of the immunoglobulin pro-
tein superfamily, present in various epithelial cells including glomerular epithelial cells.
Beside its known function as a virus receptor, it also constitutes an integral part of cell-junc-
tions. Previous studies in the zebrafish pronephros postulated a potential role of CXADR for
the terminal differentiation of glomerular podocytes and correct patterning of the elaborated
foot process architecture. However, due to early embryonic lethality of constitutive Cxadr
knockout mice, mammalian data on kidney epithelial cells have been lacking. Interestingly,
Cxadr is robustly expressed during podocyte development and in adulthood in response to
glomerular injury. We therefore used a conditional transgenic approach to elucidate the
function of Cxadr for podocyte development and stress response. Surprisingly, we could
not discern a developmental phenotype in podocyte specific Cxadr knock-out mice. In addi-
tion, despite a significant up regulation of CXADR during toxic, genetic and immunologic
podocyte injury, we could not detect any impact of Cxadr on these injury models. Thus
these data indicate that in contrast to lower vertebrate models, mammalian podocytes have
acquired molecular programs to compensate for the loss of Cxadr.
Introduction
The renal filtration barrier is composed of at least four layers, the endothelial glycocalyx, the
endothelial fenestrae, the glomerular basement membrane and the slit diaphragm (SD) in
between neighbouring podocyte foot processes [1]. This last part of the filter is composed of a
variety of different types of intercellular junctions, forming a uniquely broad, permeable and
still highly selective barrier. Beside slit-diaphragm specific components such as NEPHRIN,
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NEPH1 and PODOCIN, adherens junctional proteins i.e. CADHERIN or CATENINs as well
as tight junctional components i.e. JAM-A, OCCLUDIN, CINGULIN and ZO-1 have been
identified and localized to this junction [2–5]. Interestingly several members across different
junctional classes belong to the Immunoglobulin Superfamily (IgSF) of molecules: NEPHRIN,
NEPH1 and JAM-A [6].
Work on normal and nephrotic rat glomeruli identified the coxsackie- and adenovirus
receptor (CXADR) as another IgSF member of the podocyte SD, which was upregulated in
puromycin aminonucleoside (PAN) treated rats [7, 8]. In addition, it was demonstrated that
CXADR physically interacts with SD proteins such as PODOCIN [7]. Furthermore a morpho-
lino based CXADR knock-down approach in zebrafish suggested a role for CXADR in the ter-
minal differentiation of glomerular podocytes [9].
CXADR was identified in 1997 as the receptor mediating binding and uptake of Coxsackie
type B viruses and adenovirus type 2 and 5 [10, 11]. Subsequently it was shown that CXADR is
an integral component of tight-junctions and interacts with ZO-1, MAGI-1 and MUPP1 [12–
14]. Constitutive Cxadr knock-out mice exhibited an early embryonic lethality between E11,5
and E13,5 due to heart abnormalities [15]. Further evaluation using an inducible conditional
mouse genetic approach, revealed that loss of CXADR results in impaired electrical conduction
between the cardiac atrium and ventricle, which was underlined by a functional interaction of
CXADR with connexins [16].
To elucidate the precise role of CXADR for mammalian podocyte development, mainte-




All animal experiments were conducted according to the National Institutes of Health Guide
for the Care and Use of Laboratory Animals, as well as the German law for the welfare of ani-
mals and were approved by local authorities [G-09/23 Regierungspräsidium Freiburg]. Mice
were generated as previously described [16] and crossed using the Tg(hNPHS2-cre)295Lbh line
[17]. Mice were housed in a SPF facility with free access to chow and water and a 12h day/night
cycle. Breeding and genotyping was done according to standard procedures. To assess genetic
influence on CXADR expression the well described Cd2ap-/- on a C57Bl6 background was
used at the age of 4 weeks [18].
Developmental assessment
Individual age and sex matched animals from parallel litters on a C57Bl6/NCrl background were
used. Control animals (Cxadr fl/fl) were compared with podocyte specific (Cxadr fl/flhNphs2Cre)
mice. Collection of spot urine samples in the respective home cages was performed between 7 to 9
am at defined time points as indicated. Urinary albumin and creatinine were measured using a
fluorimetric albumin test kit (Progen, PR2005, Heidelberg, Germany) and enzymatic colorimetric
creatinine kit (LT-SYS, Lehmann, Berlin, Germany) following the manufacturer´s instructions.
Evaluation of proteinuria (expressed as the albumin to creatinine ratio) was performed as previ-
ously described [19–21]. Primary outcome was development of proteinuria.
Glomerular stress models
For some of the following stress experiments C57Bl6/NCrl mice were backcrossed to ICR mice
(Taconic, New York, USA) for at least 6 generations as indicated in the result section. All other
CXADR and Podocyte
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experiments were performed on a C57Bl6/NCrl background. We used the following well estab-
lished stress-models: A.) adriamycin, and B.) nephrotoxic serum (NTS). In each of these, con-
trol animals (Cxadr fl/fl) were compared with podocyte specific (Cxadr fl/flhNphs2Cre) mice.
Animals were allocated to the two groups based on age and sex. A.) Adriamycin (Pharmacy,
University Hospital Freiburg, Germany) was administered at a dose of 15 μg/g BW in 0,9%
saline i.v. under isoflurane anesthesia after collection of control urine. Urine was again col-
lected at 1, 2, 3, 4 and 5 weeks after injection. Mice were killed by cervical dislocation and kid-
neys harvested at 5 weeks after injection. B.) NTS of sheep origin was generously supplied
by Pierre-Louis Tharaux (INSERM PARCC, Paris, France) and generated as previously
described [22]. Briefly, mice were injected with 2μl/g BW NTS on day 0, 6μl/g BW on day 1
and 5μl/g BW on day 2. each time under isoflurane anesthesia. Urine was collected before the
respective injection on day 0 and 2 and additionally on day 3 and 4. Due to the severity of the
phenotype and in accordance with our animal proposal mice were killed by cervical dislocation
on day 4 and kidneys were harvested.
Isolation of glomeruli and podocytes
We used the magnetic bead method described by Takemoto et al. 2006 with appropriate modi-
fications [23]. Briefly, kidneys were dissected together with the abdominal aorta and trans-
ferred into dishes filled with 37°C pre-warmed Hank’s buffered salt solution (HBSS). Each
kidney was perfused slowly through the renal artery with 4 ml 37°C warm bead solution and 1
ml bead solution plus enzymatic digestion buffer [containing: collagenase 300 U/ml (Collage-
nase Type II, Worthington, Lakewood, New Jersey, USA), 1 mg/ml pronase E (P6911, Sigma,
Schnelldorf, Germany) DNase I 50 U/ml (A3778, Applichem, Darmstadt, Germany)]. Kidneys
were minced into 1 mm³ pieces using a scalpel. After addition of 3 ml digestion buffer they
were incubated at 37°C for 15 min on a rotator (100rpm). The solution was pipetted up and
down with a cut 1000μl pipette tip every 5 min. After incubation all steps were performed at
4°C or on ice. The digested kidneys were gently pressed twice through a 100 μm cell-
strainer and the flow through was washed extensively with HBSS. After spinning down, the
supernatant was discarded and the pellet resuspended in 2 ml HBSS. These tubes were inserted
into a magnetic particle concentrator and the separated glomeruli were washed twice. Podo-
cytes were isolated as previously described [24].
Morphological analysis
Kidneys were perfusion fixed in 4% phosphate buffered paraformaldehyde (Sigma, Schnelldorf,
Germany), embedded in paraffin and further processed for PAS staining. For ultrastructural
transmission electron microscopy (TEM) analysis kidneys were fixed in 4% phosphate buffered
paraformaldehyde plus 1% glutaraldehyde (Serva, Heidelberg Germany). Samples were post-
fixed in 1% osmium tetroxide in the same buffer for 1 hour and stained en bloc in 1% uranyl
acetate in 70% ethanol for 1 hour, dehydrated in ethanol, and embedded in Durcopan (Plano,
Wetzlar, Germany). Thin sections were stained with lead citrate and examined in a Zeiss Leo-
906 transmission electron microscope. For scanning electron microscopy samples were fixed
with 4% glutaraldehyde for 4 days and were then subsequently dehydrated (EtOH 50, 70, 80,
90 and 100%; 1:1 EtOH and Hexamethyldisilazan (HMDS) (Sigma, Schnelldorf, Germany) for
1 hour and 30 minutes 100% HMDS, afterwards solvent was allowed to evaporate) and coated
with Gold (Zeiss Semco Nanolab7, Polaron Cool Sputter Coater E 5100, Balzer Cpd 020) [25].
Image acquisition was performed using a Leo 1450 VP scanning electron microscope.
CXADR and Podocyte
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Western Blot and Immunofluorescence
Kidneys or isolated glomeruli were glass-glass-homogenized in lysis buffer (containing 20 mM
CHAPS and 1% Triton X-100). After centrifugation (15,000x g, 15 min, 4°C) protein concen-
tration was determined by DC Protein-Assay (Bio-Rad, Hercules, California, USA). Equal
amounts of protein were separated on SDS page. For immunofluorescence kidneys were frozen
in OCT compound and sectioned at 4–5 μm (Leica Kryostat, Leica, Wetzlar, Germany). The
sections were fixed with 4% paraformaldehyde, blocked in PBS containing 5% BSA + 5% Nor-
mal Donkey Serum (Jackson ImmunoResearch, Suffolk, Great Britain) and incubated for 45
min with primary antibodies as indicated. For co-stainings with CXADR initial fixation was
performed using methanol at -20° for 10 minutes. After several PBS rinses, fluorophore-
conjugated secondary antibodies (Life Technologies, Darmstadt, Germany) were applied for
30 minutes. Image acquisition was done either using a confocal imaging set up (Zeiss LSM 510
upright microscope, Zeiss, Germany), equipped with a Plan-Apochromat 63x/1.4 Oil M27
objective or a epifluorescence widefield imaging setup (Zeiss Axioplan 2 upright + Axiocam
MRc5 digital camera)). Image recording was performed with the appropriate software (Zen
black Software or Axiovision LE46—Zeiss). The following antibodies were used: anti-CXADR
(HPA030411, Atlas Antibodies, Stockholm, Sweden), anti-CXADR (H300, sc15405, Santa
Cruz Biotechnology, Heidelberg, Germany) anti-NIDOGEN (Clone ELM1, Millipore, Darm-
stadt, Germany), anti-NEPHRIN (GP-N2, Progen, Heidelberg, Germany), anti-ZO-1 (Clone
ZO1-1A12, Life Technologies, Karlsruhe, Germany), anti-β-Actin (Clone AC-15, Sigma,
Schnelldorf, Germany), anit-CD2AP (generous gift by Andrey Shaw, Washington University,
St. Louis, USA), FITC-LTG and Texas-Red- DBA (Vectorlabs, California, USA), Hoe33342
and respective Alexa-Fluor 2nd antibodies (all Life Technologies, Karlsruhe, Germany).
In-Situ Hybridization
Amouse kidney cDNA library served to clone a fragment of the coding sequence of mouse
Cxadr. The following primers were used: ISHcxadrMluF CGCGGGACGCGTACCAGGG
ACCACTGGACATT and ISHcxadrNotB1: CGCGGGGCGGCCGCGCGCACGTTCAAAG
TCTTCA, yielding a 843 bp PCR product. PCR fragments were inserted into pBluescript SK+
vector (Invitrogen, Carlsbad, CA, USA) using Not I and Mlu I restriction sites. pBluescript SK+
vector was linearized and digoxigenin-(DIG)-labeled antisense riboprobes were generated
using T7-RNA-polymerase (Ambion, Karlsruhe, Germany). For paraffin ISH sections, slides
were progressively rehydrated and permeabilized with proteinase K for 3 min. After prehybri-
dization (60 min), hybridization with DIG-UTP probes took place overnight in standard saline
citrate (SSC; pH 4.5; containing 50% formamide) at 65–70°C. Specimens were then incubated
with alkaline phosphatase-conjugated anti-DIG Fab fragments (Roche, Mannheim, Germany)
at a dilution of 1:4,000 overnight at 4°C. Alkaline phosphatase was detected using chromogenic
conversion of NBT/BCIP (Roche, Mannheim, Germany). To avoid drying up of the slides dur-
ing hybridization, we placed them in a humidity chamber containing 5×SSC and 40% formam-
ide. Slides were then progressively dehydrated, washed in xylol, and mounted.
Statistics
Data are expressed as mean ± SEM. Statistical comparisons were performed using the Graph-
Pad Prism Software Package (Ver.6, GraphPad Software, La Jolla, California, USA) with two-
tailed Student’s t-test or ANOVA including respective corrections where indicated. Differences
with p values below 0.05 were considered significant.
CXADR and Podocyte
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Results
Cxadr is highly expressed during kidney development.
Cxadr expression was analyzed using in-situ hybridization. Beside a predominant CNS signal,
Cxadr was strongly expressed in several epithelial tissues including gut, lung and kidney (Fig
1A, 1B, 1C and 1D). Within the kidney Cxadr was localized to glomerular podocytes and epi-
thelial cells of several tubular segments including the proximal tubule and the thick ascending
limb of Henle (Fig 1E and 1F +S1 Fig). Western blot analysis of 6 week old animals confirmed
protein expression in heart, kidney, lung, brain and isolated murine primary podocytes (Fig
1G). P1 kidneys were used to analyze the Cxadr expression during glomerular maturation (Fig
1H, 1I, 1J and 1K): In the S-shaped body stage CXADR was first expressed in epithelial cells
committed to become parietal epithelial cells and podocytes, but not in cells destined to
become proximal tubular cells (Fig 1H). Podocytes and parietal epithelial cells continued to
express CXADR while mesangial and endothelial cells never showed a detectable signal (Fig 1J
and 1K + S1 Fig). From the early capillary loop stage to mature glomerula CXADR co-
localized with the SD protein NEPHRIN (Fig 1L and 1M). In addition, a strong linear signal of
CXADR along Bowman’s capsule, representing CXADR expression in parietal epithelial cells,
was observed (Fig 1L”`, white asterisks). Interestingly, the expression of CXADR in podocytes
vanished by 6 weeks of age, while parietal epithelial cell expression remained constantly high
(S1C–S1E Fig).
Podocyte specific knock-out of Cxadr does not impair glomerular
development.
We generated podocyte specific Cxadr deficient animals, using the established hNPHS2Cre sys-
tem (Fig 2A). Westernblot of glomerular lysates and immunofluorescence staining confirmed
CXADR expression in wild-type animals, which was up-regulated upon NTS treatment and
absent in podocyte specific Cxadr deficient mice (Fig 2B, 2C and 2D). The specificity of our
conditional approach was demonstrated by the maintained robust parietal epithelial cell
expression of CXADR in both genotypes. (Fig 2D”`—white arrows). Using immunofluores-
cence we evaluated the abundance and distribution of the slit diaphragm proteins NEPHRIN
and PODOCIN as well as of the tight junctional protein ZO-1. At all three developmental
stages examined–capillary loop stage, early and mature glomerulus glomerulus—we neither
found any decisive difference in staining intensity nor any difference in protein distribution
within podocytes of control and podocyte–specific Cxadr knock-out animals (Fig 2E–2J, S2A–
S2F Fig). We therefore conclude that absence of CXADR does not lead to any major detectable
changes in NEPHRIN, PODOCIN and ZO-1, at least with our methods used. Albumin excre-
tion between genotypes was only slightly significantly different at P2 but not on all other five
tested time points (Fig 3A, n = 5–10 per time point and group). Similarly, light microscopy at
week 3, as well as SEM and TEM did not show any obvious histological or ultrastructural
abnormalities (Fig 2B–2E).
Fig 1. Cxadr is highly expressed during kidney development. (A-D) In-Situ-Hybridization showed intense expression of Cxadr in E15.5 embryos,
especially in the nervous system, gut, lung and kidney. (E&F) After birth at P1 and P14Cxadr could be detected in glomerular cells as well as in the nephron
(thick ascending limb of Henle). (G)Western blot confirmed CXADR expression in heart, kidney, lung, brain and more specifically in isolated murine
podocytes. (H-K)Developmental assessment of Cxadr expression during kidney development started in the S-shaped body phase where podocytes and
parietal epithelial cells formed a continuous stretch of cells. (L&M) In both, podocytes (arrows) and parietal epithelial cells (asterisk) CXADR could be
robustly detected in the early capillary loop stage, while mature glomeruli only possessed reduced amounts of CXADR in podocytes.
doi:10.1371/journal.pone.0129424.g001
CXADR and Podocyte
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Adriamycin enhances podocyte specific CXADR expression, but lack of
CXADR does not influence the course of Adriamycin induced FSGS.
Next we exposed control and podocyte deficient animals to adriamycin. This anthracycline
antibiotic is known to cause proteinuria and a FSGS like phenotype when administered to mice
on a sensitive genetic background (e.g. ICR, balb/c), while it does not cause an overt podocyte
phenotype in resistant mouse strains (i.e. C57Bl6/NCrl) [26]. Hence, depending on the genetic
background the adriamycin stress model allows to test for either sensitization or protection in
the context of the respective gene knockout. Using immunofluorescence and western blot we
Fig 2. Podocyte specific knock-out ofCxadr does not impair glomerular development. (A) Targeting strategy leading to podocyte specific deletion of Exon
1. (B) In decapsulated wild-type glomeruli CXADR protein could be detected by western blot. NTS stimulates CXADR expression. In podocyte specificCxadr
deficient animals no protein could be detected, indicating that all detected glomerular CXADR protein is of podocyte origin. (C&D) Immunofluorescence analysis
showed co-localization of CXADR and NEPHRIN in wild-type animals, which was lost in podocyte specific knock-out animals. CXADR expression in parietal
epithelial cells (arrows in D”‘) was unaffected by our targeting approach. (E-J) Analysis of ZO-1 and NEPHRIN expression at three decisive time points during
glomerular development in control andCxadr podocyte specific knock-out animals reveals no difference with regard to expression abundance and distribution of
both a slit-diaphragm and a tight junctional protein.
doi:10.1371/journal.pone.0129424.g002
Fig 3. Glomerular function, histology and ultrastructure are maintained in podocyte specificCxadr knock-out animals. (A) Functional assessment
only showed a slightly elevated albuminuria inCxadr deficient animals at P2 which was lost during further maturation of the kidney. (B&C)Histology of
glomeruli was normal in podocyte deficient Cxadr animals as was (D&E) ultrastructural assessment by SEM (D–D”, E–E”) and TEM (D”‘, E”‘).
doi:10.1371/journal.pone.0129424.g003
CXADR and Podocyte
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were able to demonstrate that adriamycin upregulates CXADR in control podocytes (Fig 4A,
4B, 4D and 4E). Inversely to CXADR expression, the expression level of the slit diaphragm
molecules NEPHRIN and PODOCIN was greatly reduced in both genotypes (Fig 4F and 4G–
staining was performed on ICR backcrossed animals of both respective genotypes). This was in
contrast to ZO-1 which showed virtually constant expression levels and equal distribution
between health and disease in all mice (Fig 4H and 4I). However, despite profound up-
regulation of CXADR on both genetic backgrounds we could not identify any clinical func-
tional difference between genotypes over the course of five weeks (Fig 4C, 4J and 4K; C57Bl6/
NCrl background: control group n = 3, Cxadr fl/flhNphs2Cre n = 4; ICR background: control
group n = 6, Cxadr fl/flhNphs2Cre n = 7).
Nephrotoxic serum (NTS) enhances podocyte specific CXADR
expression, but lack of CXADR does not influence the course of NTS
induced disease.
Subsequently we examined whether CXADR up-regulation is limited to toxic nephrotic states
or whether this also applies to genetic or immunological conditions. Indeed, using an estab-
lished genetic model of nephrotic syndrome (Cd2ap knockout animals) and sheep derived
nephrotoxic serum (NTS), we could demonstrate that in both conditions tested, CXADR was
strikingly up-regulated (Fig 5A–5C, 5E and 5F + S3A and S3B Fig). We therefore treated wild-
type and Cxadr podocyte deficient animals with NTS, but again despite marked proteinuria
within 4 days after administration of NTS, we could not detect any difference between respec-
tive genotypes (Fig 4D, 4G, 4H and 4I; control group n = 6, Cxadr fl/flhNphs2Cre n = 6).
Discussion
Podocyte function and maintenance is regulated by precisely orchestrated cell-cell contacts.
The discovery of the molecular composition of the SD has profoundly changed our under-
standing of glomerular filtration and function. However, the dynamic changes, molecular
make up and intermolecular interactions at the SD remain incompletely understood. Here we
identify the IgSF member CXADR to be specifically regulated and expressed in developing and
injured mammalian podocytes. CXADR shows an early and specific expression in precursors
of podocytes and parietal epithelial cells, starting in the S-shape body phase during glomerular
development. Yet, while podocyte specific expression vanishes over the first six weeks of life,
expression in parietal epithelial cells stays prominent through-out life. Given the potential role
of parietal epithelial cells for podocyte regeneration and repair, this might indicate that Cxadr
is a marker of immature podocytes which is lost during podocyte differentiation [27]. This loss
of CXADR is actually paralleled by the formation of the slit-diaphragm out of a tight-junction
based precursor [1]. Developmental reduction of Cxadr expression levels seems to be a com-
mon theme and has been described for brain and heart before [28, 29].
Fig 4. Adriamycin enhances podocyte specific CXADR expression, but lack of CXADR does not influence the course of Adriamycin induced FSGS.
(A) In adult wild-type animals CXADRwas restricted to parietal epithelial cells (white arrows). (B) Administration of Adriamycin led to an increased glomerular
CXADR expression which could be localized to glomerular podocytes using co-labeling experiments with NEPHRIN (white arrow heads). (C) Adriamycin
injection scheme and subsequent urine measurements. (D&E)Western blots of decapsulated glomerular lysates were used to quantify CXADR expression in
podocytes which indeed was upregulated two-fold. We next assessed abundance and distribution of the slit diaphragmmolecules PODOCIN and NEPHRIN
after adriamycin injection, and could not discern any differences between the two genotypes (F-F”, G-G” dashed lines-podocyte compartment). In contrast to
NEPHRIN the pattern of ZO-1 expression was largely maintained in both genotypes. (H-H”, I-I” dashed lines—podocyte compartment).We next assessed
functional consequences on two different mouse genetic background strains. (J)Wild-type and knock-out animals on a C57Bl6/NCrl were analysed to check for
increased susceptibility of knock-out animals while (K)wild-type and knock-out animals on an ICR background were used to test for a protective effect of
podocyte specific CXADR deficiency. On both mouse genetic backgrounds we could not discern a difference between wild-type and knock-out mice over
a follow-up period of 5 weeks.
doi:10.1371/journal.pone.0129424.g004
CXADR and Podocyte
PLOS ONE | DOI:10.1371/journal.pone.0129424 June 15, 2015 10 / 15
CXADR and Podocyte
PLOS ONE | DOI:10.1371/journal.pone.0129424 June 15, 2015 11 / 15
Interestingly, and in contrast to previously published results in the zebrafish pronephros
[9], conditional podocyte specific knock-out in mice does not lead to a developmental pheno-
type. Obviously, it is known from previous studies that the hNPHS2 promotor is only active
from approximately embryonic day E 14.0 onwards when glomerular development proceeds
from the S-shaped body towards the early capillary loop stage [30]. As mentioned, CXADR is
already highly expressed in the S shaped stage and hence early essential roles might be missed
by a relatively late recombination event. Yet, hNPHS2-Cremediated knock-out seems efficient
with regard to CXADR protein reduction, as we could not detect any protein anymore in late
capillary loop stages of glomerular development in respective knock-out animals.
As shown with different types of toxic, genetic and immunological glomerular injury mod-
els, Cxadr expression is robustly upregulated during podocyte injury. It could therefore be used
as a podocyte stress marker, similarly to down regulation of SESTRIN in parietal epithelial cells
[31, 32]. Interestingly, upregulation of CXADR during disease has been previously described in
the heart under various conditions i.e. autoimmune inflammation, infarction and dilated car-
diomyopathy [29, 33, 34]. A potential functional role of CXADR up regulation in response to
glomerular injury is unfortunately not being revealed by our data. In fact, our analysis indicates
that presence or absence of podocyte CXADR does not change the course of injury or repair, at
least within the models and time lines evaluated in this study. In addition expression and distri-
bution of other decisive slit diaphragm and tight junctional molecules was not changed. This in
our opinion at least allows two conclusions: 1. There seems to be a redundancy with regard to
Super Ig cell adhesion molecules possessing only 2 extracellular IgG domains and other mem-
bers expressed in podocytes could potentially take over CXADR’s function [24, 35]. 2. ZO-1
based tight junctions forming during podocyte injury do not rely on additional CXADR
expression and form stable cell-cell contacts themselves.
As CXADR expression within the glomerulum is much more prominent in parietal epithe-
lial cells, future studies might be warranted to address the role of CXADR in these specialized
epithelial cells of Bowman’s Capsule. This not only applies to their unchallenged physiologic
state but also to any changes which occur in glomerular diseases such as rapid progressive
glomerulonephritis, where proliferation and crescent formation of parietal epithelial cells are
distinguished hallmarks.
Supporting Information
S1 ARRIVE Checklist. Supplemental Information ARRIVE. A completed ARRIVE checklist
concerning all animal experiments in this manuscript is given.
(PDF)
S1 Fig. Non-podocyte renal expression of CXADR. (A&B) CXADR was expressed in proxi-
mal as well as distal parts of the renal tubular system, as demonstrated by co-labeling with
either LTG or DBA-lectins. Here CXADR localizes clearly to cell-cell contacts of renal tubular
epithelial cells. (C-E) Immunofluorescence at different developmental time points demon-
strated a reduction of podocyte CXADR expression, whereas a strong signal was still present in
Fig 5. Nephrotoxic serum (NTS) enhances podocyte specific CXADR expression, but lack of CXADR does not influence the course of NTS induced
disease. (A-C)On both d4 and d5 after NTS injection CXADR was increased in glomerular podocytes as shown in co-labeling experiments with NEPHRIN
(control: white arrows—parietal epithelial cells, NTS: arrow heads—podocytes). As can be easily depicted from the NEPHRIN specific panel (A”, B”, C”)
NEPHRIN abundance is greatly reduced during the course of the disease, underlining the severity of the chosen stress model. (D) Schematic of the injection
scheme and follow-up using urine collections. (E&F)Western blot using decapsulated glomerular lysates was used to quantify CXADR expression which
was increased two fold 5 days after NTS injection. (G&H) As shown with immunofluorescence stainings CXADR induction was absent in podocyte specific
Cxadr knock-out animals. (I) Proteinuria developed similarly in wild-type and knock-out animals showing no functional differences.
doi:10.1371/journal.pone.0129424.g005
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parietal epithelial cells of adult animals.
(TIF)
S2 Fig. Developmental expression of the bona fide slit diaphragm proteins NEPHRIN and
PODOCIN in control and podocyte specific Cxadr-/- mice. Assessment of NEPHRIN and
PODOCIN expression at different developmental stages–capillary loop, early glomerulus,
mature glomerulus–in control (A-A”, C-C”, E-E”) and podocyte specific Cxadr-/- animals
(B-B”, D-D”, F-F”) was performed using immunofluorescence. Loss of CXADR does not lead
to changes in abundance and distribution of neither NEPHRIN nor PODOCIN.
(TIF)
S3 Fig. CXADR is also upregulated in podocytes in the Cd2ap-/-model of genetic glomeru-
lar disease. (A&B) CD2AP knockout animals exhibited a clear upregulation of CXADR
expression in podocytes as demonstrated by immunofluorescence staining of CXADR and
respective co-labeling with NEPHRIN.
(TIF)
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